COMPANY PRESENTATION
Conference Call
FY 2025 Financial results
March 16th, 2026
2025 Financials - Euro '000
P&L | 31/12/2024 | % | 31/12/2025 unaudited | % | Var.% |
Revenues | 565.846 | 590.849 | 4,4% | ||
EBIT | 78.309 | 13,8% | 77.796 | 13,2% | -0,7% |
Revenues | 31/12/2024 | % | 31/12/2025 | % | Var.% |
Medical | 410.401 | 72,5% | 428.648 | 72,5% | 4,4% |
Industrial | 155.444 | 27,5% | 162.201 | 27,5% | 4,3% |
13 mln 19 mln 24 mln 19 mln
**D&A= Depreciation, Accruals and Devaluation
* Nopat =Ebit-Income tax
***NWC= Net Working Capital
Euro '000 | 31/12/2024 | % | 31/12/2025 unaudited | % | Var. % |
Medical | 410.401 | 72,5% | 428.648 | 72,5% | 4,4% |
Industrial | 155.444 | 27,5% | 162.201 | 27,5% | 4,3% |
Revenues | 565.846 | 100,0% | 590.849 | 100,0% | 4,4% |
Gross margin | 245.637 | 43,4% | 259.758 | 44,0% | 5,7% |
Operating Expenses | 55.092 | 9,7% | 59.879 | 10,1% | 8,7% |
Staff espenses | 98.770 | 17,5% | 107.047 | 18,1% | 8,4% |
EBITDA | 91.775 | 16,2% | 92.831 | 15,7% | 1,2% |
Depr., amort., accruals | 13.467 | 2,4% | 15.035 | 2,5% | 11,6% |
EBIT | 78.309 | 13,8% | 77.796 | 13,2% | -0,7% |
Net financ.income(charges) | 802 | 0,1% | (813) | -0,1% | |
Other income (expense) net | 4.993 | 0,9% | (2.729) | -0,5% | |
EBT | 84.104 | 14,9% | 74.255 | 12,6% | -11,7% |
Income taxes | (21.227) | -3,8% | (23.497) | -4,0% | 10,7% |
Discontinued operations | (10.372) | -1,8% | (6.573) | -1,1% | -36,6% |
Minorities | (892) | -0,2% | (770) | -0,1% | -13,7% |
NET INCOME | 51.613 | 9,1% | 43.415 | 7,3% | -15,9% |
Euro '000 | 31/12/24 | 31/12/25 | Var.% |
unaudited | |||
Total non current assets | 103.237 | 118.766 | 15,0% |
Net Working Capital | 199.826 | 184.586 | -7,6% |
Other receivables/payables ST | (32.675) | (31.183) | -4,6% |
Net financial position | 110.559 | 172.212 | 55,8% |
Long term liabilities | 16.071 | 16.907 | 5,2% |
Net Equity | 410.802 | 427.474 | 4,1% |
Discontinued operation | 45.926 | 0 | -100,0% |
Net capital employed | 300.243 | 255.262 | -15,0% |
Net Working Capital on sales | 35,3% | 31,2% | |
ROCE (EBIT/Net capital employed) Operating Capex | 26,1% 11.623 | 30,5% 19.376 |
+4%
2024
2025
235,5
245,3
+7% +2% +5%77,4 82,7
16,2
16,9
79,6 81,1
Medical: +4%
+5%2024
2025
104,5 110,0
-3% +18%28,8
28,1
-23%17,0
20,0
4,3 3,3
Service
Laser sources
Marking
Cutting
Service
Physioth.
Surgical
Aesthetic
in Euro million
Industrial: +4%
Medical
+2%2024
2025
+7% +14%247,2
137,4
44,1
38,7
128,5
243,2
Medical: +4%
in Euro million
Industrial: +4%
+26%Italy
RoEU
RoW
Italy
RoEU
RoW
69,1
45,8
40,6
38,5
36,6
87,1
-16% -10%Industrial
2024
2025
Revenues increase: ~ +5% EBIT% 2026 > EBIT% 2025
CONTACTS
El.En. S.P.A.
Enrico Romagnoli
Investor Relations Manager
tel. +39 055-8826807
E-mail: finance@elen.it
POLYTEMS HIR
Financial Communication, IR and Press Office Bianca Fersini Mastelloni - b.fersini@polytemshir.it Silvia Marongiu - s.marongiu@polytemshir.it
Tel. +39 06-69923324
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |